Caribou Biosciences filings document a clinical-stage CRISPR genome-editing biopharmaceutical company focused on allogeneic CAR-T therapies. Recent 8-K reports furnish quarterly and annual financial results, cash and operating-plan disclosures, business updates, and Regulation FD disclosures covering vispa-cel and CB-011 clinical and FDA-related developments.
Proxy materials describe annual meeting matters, board elections, auditor ratification, and proposed charter governance changes for the Delaware corporation. Other event filings record public-company status matters, including Nasdaq bid-price compliance notices and product-candidate regulatory designations.
Caribou Biosciences, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a business update. The press release is attached as Exhibit 99.1 to this Current Report and is incorporated by reference into the disclosure.
The filing specifies that the Item 2.02 information (including Exhibit 99.1) is being furnished and therefore is not deemed "filed" under the Exchange Act, meaning it is provided for investor information without extending Section 18 liabilities. The 8-K itself does not include separate financial tables or statements beyond the furnished press release.